Monday 21 to Tuesday 22 September 2026. An opportunity to broaden your understanding of the capabilities and potential of MRI guidance in radiotherapy planning and treatment verification. We invite ...

PENELOPE B is a phase III international, multicentre, randomised, placebo-controlled, double-blind trial comparing the efficacy and safety of adding palbociclib to standard hormone therapy vs standard ...

Need to find a specific expert or member of a research group or division? Just search by role, division, name or browse our researchers A-Z.

What is the study about? IMPORT LOW investigates whether a more targeted type of radiotherapy for people with early breast cancer can reduce side effects without reducing how well the treatment works.

The dedication of these charities, set up when a family has been touched by cancer, drives forward our research immeasurably. We are so grateful to work with such passionate organisations and receive ...

Last month, DeepMind published the much anticipated, detailed methodology underlying the latest version of AlphaFold – the UK-based science company’s powerful AI system that blew away its rivals in ...

A spit test, where a sample can be collected at home, is more accurate at identifying future risk of prostate cancer for some men than the current standard PSA blood test, a new study reports. Results ...

As we enter 2026, scientists at The Institute of Cancer Research, London, share the developments expected this year that could soon change how cancer is treated – from technologies designed to deliver ...

The overuse of CT scans could cause over 100,000 cases of cancer in the US – with almost 10,000 cases in children, researchers have warned. According to a new modelling study, published in the journal ...

Experts at The Institute of Cancer Research, London, have responded to the draft recommendation from the National Screening Committee (NSC) to implement a targeted prostate cancer screening programme ...

The Institute of Cancer Research, London, has welcomed the approval of a new combination of two drugs for a rare form of ovarian cancer by the US regulatory body the Food and Drug Administration (FDA) ...